{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:20:36Z","timestamp":1761006036563,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcardioanesthesia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.jvca.2023.01.026","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T03:31:40Z","timestamp":1675308700000},"page":"839-840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dispelling Dogma: Milrinone Therapy Is Safe and Effective in Renally-Impaired Patients, and We Knew This!"],"prefix":"10.1053","volume":"37","author":[{"given":"Nicolas","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Reeves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasir","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Essandoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2021","series-title":"Milrinone. StatPearls","author":"Ayres","key":"10.1053\/j.jvca.2023.01.026_bib0001"},{"key":"10.1053\/j.jvca.2023.01.026_bib0002","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.jvca.2023.01.026_bib0003","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/CRD.0000000000000165","article-title":"Milrinone dosing and a culture of caution in clinical practice","volume":"26","author":"Chong","year":"2018","journal-title":"Cardiol Rev"},{"key":"10.1053\/j.jvca.2023.01.026_bib0004","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1053\/j.jvca.2022.11.027","article-title":"Renal dysfunction and arrhythmia association in patients receiving milrinone after cardiac surgery","volume":"37","author":"Valkovec","year":"2023","journal-title":"J Cardiothorac Vasc Anes"},{"key":"10.1053\/j.jvca.2023.01.026_bib0005","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0033-0620(05)80005-2","article-title":"Electrophysiologic and proarrhythmic effects of intravenous inotropic agents","volume":"38","author":"Tisdale","year":"1995","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1053\/j.jvca.2023.01.026_bib0006","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial","volume":"287","author":"Cuffe","year":"2002","journal-title":"JAMA"},{"key":"10.1053\/j.jvca.2023.01.026_bib0007","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1161\/CIRCHEARTFAILURE.107.746933","article-title":"Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF)","volume":"1","author":"Klein","year":"2008","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.jvca.2023.01.026_bib0008","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.2042-7158.1995.tb05853.x","article-title":"Dose regimen adjustment for milrinone in congestive heart failure patients with moderate and severe renal failure","volume":"47","author":"Woolfrey","year":"1995","journal-title":"J Pharm Pharmacol"},{"key":"10.1053\/j.jvca.2023.01.026_bib0009","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1053\/j.jvca.2022.01.036","article-title":"Renal replacement therapy and mortality in venoarterial extracorporeal membrane oxygenation patients: The devil is in the details","volume":"36","author":"Kumar","year":"2022","journal-title":"J Cardiothorac Vasc Anes"}],"container-title":["Journal of Cardiothoracic and Vascular Anesthesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077023000472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053077023000472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:01:16Z","timestamp":1760947276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053077023000472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":9,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1053077023000472"],"URL":"https:\/\/doi.org\/10.1053\/j.jvca.2023.01.026","relation":{},"ISSN":["1053-0770"],"issn-type":[{"type":"print","value":"1053-0770"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dispelling Dogma: Milrinone Therapy Is Safe and Effective in Renally-Impaired Patients, and We Knew This!","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiothoracic and Vascular Anesthesia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2023.01.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1053\/j.jvca.2022.11.027","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}